Last updated: July 3, 2026
United Therapeutics v. Liquidia (24-1658) Litigation Summary: What the Case Claims, Where It Sits, and What It Means for Lung Disease IP
United Therapeutics Corporation sued Liquidia Technologies, Inc. in case 24-1658 alleging patent infringement tied to Liquidia’s inhaled treprostinil platform. The core business question is whether United Therapeutics can extend exclusivity and enforce patent coverage against Liquidia’s next-generation inhalation products, including any commercially relevant “dry powder” or other inhalation dosage formats that compete in pulmonary arterial hypertension (PAH).
What is the United Therapeutics v. Liquidia Technologies case 24-1658 about?
High-level answer: The dispute centers on asserted United Therapeutics patents covering inhaled treprostinil technology and/or associated methods, with Liquidia accused of infringing through development and/or marketing activities connected to its inhaled treprostinil product line.
What product category is at issue?
United Therapeutics is the dominant patent holder for inhaled treprostinil in PAH, with its flagship inhaled treprostinil being marketed in the United States as Tyvaso (and related next-generation systems such as Tyvaso DPI). Liquidia is positioned as a competitor in inhaled treprostinil delivery and has advanced inhalation formulations (including dry powder inhaler concepts) that can fall into the same therapeutic and regulatory landscape.
What typically drives these patent cases in inhaled treprostinil?
In these families, asserted claims usually cluster in one or more of the following IP buckets:
- Formulation and particle engineering (eg, powder attributes, aerosolization performance, dispersibility)
- Device integration and administration workflow (inhaler use, dosing steps, delivery control)
- Manufacturing methods (process steps for forming inhalable particles or composite units)
- Method-of-use (treating PAH using inhaled treprostinil under specified dosing parameters)
The complaint in 24-1658 is described as a patent infringement matter, meaning United Therapeutics is asserting that Liquidia’s product and/or product development activity falls within the scope of specific claims in the asserted patents.
Which patents did United Therapeutics assert against Liquidia in 24-1658?
Answer: The litigation in 24-1658 is “asserted patent infringement” tied to United Therapeutics’ inhaled treprostinil estate, but the specific asserted patent numbers, claim groupings, and assignee chain are not present in the information provided in this prompt. Without the complaint or court docket entries listing asserted patents, a correct, complete enumeration of the patents cannot be produced.
Why patent identification matters for litigation analysis
Without the asserted patent list, it is not possible to:
- Map the case to expiration and exclusivity windows
- Identify whether the theory is formulation vs method-of-use vs device
- Evaluate prior art vulnerability
- Determine whether Liquidia has a meaningful noninfringement or invalidity pathway based on claim construction trends
Because this request asks for a “litigation summary and analysis,” including case meaning for exclusivity and launch risk, the asserted patent set is essential.
Where is case 24-1658 procedurally (complaint, motions, claim construction, trial)?
Answer: The procedural posture of 24-1658 cannot be stated accurately from the information provided. A litigation summary that depends on deadlines, Markman timing, dispositive motion outcomes, settlement signals, or trial scheduling requires docket-specific facts.
How procedural posture changes risk
- Early-stage pleadings: higher chance of amended claims and narrower infringement snapshots
- Claim construction phase: higher leverage for design-around strategies
- Summary judgment motions: strong invalidity or noninfringement filtration risk
- Settlement or dismissal: commercial timeline impact via licensing or covenant terms
No docket entries or order dates are available in the prompt content, so the case posture cannot be pinned down.
What infringement theories does United Therapeutics use against Liquidia?
Answer: United Therapeutics’ theories in inhaled treprostinil disputes typically combine product infringement (direct and/or indirect) with method-of-use infringement where dosing and administration are claimed. But the specific theories pleaded in 24-1658 are not available in the information provided.
Common infringement theories in inhaled treprostinil litigation
- Literal infringement: Liquidia’s formulation/device matches claim elements as construed
- Infringement under the doctrine of equivalents: argues substantially similar particle or delivery behavior
- Induced or contributory infringement: focused on training, instructions, or components that are especially made for the patented system
- Method-of-use infringement: directed at treating PAH by inhaled administration with particular dosing steps
A precise “what it alleges” summary requires the complaint’s count-by-count infringement allegations and mapping tables, which are not included.
How strong is United Therapeutics’ patent estate versus Liquidia’s design-around options?
Answer: A strength analysis requires the asserted claim set and their likelihood of surviving construction and invalidity challenges. The asserted patents and claim scope are not available, so a compliant strength assessment cannot be produced.
What patent strength analysis normally covers in this niche
- Construction of key technical limitations (particle size distribution, powder flowability, aerosol generation metrics)
- Written description support and enablement scrutiny for formulation claims
- Obviousness landscape anchored to aerosol science and inhalation device prior art
- Definiteness and claim clarity for method-of-use or dosing limitations
- Validity leverage based on prosecution history and narrowing amendments
Without asserted patents and claim language, an accurate scorecard would be speculative.
Does the case connect to Orange Book listings or FDA generic/biosimilar pathways?
Answer: The relationship to Orange Book or FDA regulatory pathway cannot be determined from the provided prompt.
How inhaled treprostinil cases usually tie to FDA filings
In treprostinil inhalation disputes, patent litigation often aligns with:
- Hatch-Waxman mechanisms (Paragraph IV) for small molecule generics
- 505(b)(2) pathway disputes for reformulations or new dosage forms
- Brand-to-brand disputes over next-generation devices (patents can drive exclusivity or commercial switching)
But the prompt does not provide Liquidia’s specific FDA pathway in relation to 24-1658, nor does it provide any Orange Book patent listing for the relevant drug product.
When does exclusivity end for the contested inhaled treprostinil products?
Answer: Exclusivity timelines depend on the specific marketed product(s), their listed patents, and whether the case targets composition, method, or device claims. No exclusivity or expiration dates are included in the provided information, so a timeline cannot be computed.
What timelines typically matter
- Patent expiration dates for composition and method patents
- Potential pediatric exclusivity extensions
- Orange Book-listed patents tied to approval or supplemental approvals
- Any 30-month stay triggered by a statutory challenge (if Hatch-Waxman applies)
This requires listing-specific data absent from the prompt.
What generic entry risks exist for Liquidia if United Therapeutics wins or loses?
Answer: Launch risk depends on:
- Which claims survive construction
- Whether final judgment includes injunction scope
- Whether Liquidia can design around claim limitations without losing therapeutic performance
Those outcomes require docket orders and verdict or settlement documents, which are not provided.
What patent litigation affects United Therapeutics’ competitive position against Liquidia?
Answer: The competitive impact is directionally that United Therapeutics seeks to prevent Liquidia from entering and competing in inhaled treprostinil space under infringement exposure. But the case-specific effect cannot be quantified without procedural outcome details, injunction requests, and settlement terms if any.
Key business levers that usually flow from these cases
- Injunctive relief scope and “workaround” permission
- Licensing structure and royalties (if settled)
- Carve-outs by formulation/device variant
- Timing of entry relative to patent expiry and exclusivity
No such levers are present in the prompt.
Did the parties settle, dismiss, or reach a consent judgment in 24-1658?
Answer: Settlement or dismissal status cannot be determined from the provided information.
Settlement patterns in this technical space
- License with paid-up front and ongoing royalties
- Settlement with an agreed “design-around” feature
- Stipulated dismissal after claim amendments or trial outcomes
None of these data points are available in the prompt.
Key Takeaways
- Case identity: United Therapeutics Corporation v. Liquidia Technologies, Inc., docket 24-1658, is a patent infringement dispute in inhaled treprostinil technology.
- Material missing for full litigation analysis: The prompt does not include the asserted patent numbers, infringement counts, procedural posture, or docket outcomes. Without those inputs, a complete and accurate litigation summary and business-grade analysis cannot be produced.
FAQs
-
What court heard United Therapeutics v. Liquidia 24-1658?
Not determinable from the provided prompt.
-
What patents are asserted in 24-1658?
Not provided in the prompt.
-
Is 24-1658 tied to an FDA Paragraph IV filing?
Not provided in the prompt.
-
Can Liquidia design around asserted treprostinil inhalation claims?
Requires asserted claim language and outcomes not provided in the prompt.
-
What is the likely commercial timeline impact of 24-1658?
Requires docket status, injunction posture, and any settlement terms not provided in the prompt.
References (APA)
- No sources were provided in the prompt for case 24-1658 docket entries, complaint details, or court orders.
